Synthesis of α-Ketoamides from β-Ketonitriles and Primary Amines: A Catalyst-Free Oxidative Decyanation-Amidation Reaction
作者:Ya-Kai Zhang、Bin Wang
DOI:10.1002/ejoc.201900900
日期:2019.9.8
A catalyst‐free oxidative decyanation–amidation reaction is developed for the synthesis of α‐ketoamides using β‐ketonitriles, primaryamines, and hydrogen peroxide sodium carbonate adduct (Na2CO3·1.5H2O2). This method is a valuable and simple strategy for the decyanation reaction.
使用β-乙腈,伯胺和过氧化氢碳酸钠加合物(Na 2 CO 3 · 1.5H 2 O 2)开发了无催化剂的氧化脱氰-酰胺化反应,用于合成α-酮酰胺。该方法是用于脱氰反应的有价值且简单的策略。
Catalytic Enantioselective Pictet–Spengler Reaction of α‐Ketoamides Catalyzed by a Single H‐Bond Donor Organocatalyst
作者:Rémi Andres、Qian Wang、Jieping Zhu
DOI:10.1002/anie.202201788
日期:2022.5.2
A simple prolinamide bearing a single H-bond donor urea functioncatalyzes the Pictet–Spengler reaction between tryptamines and α-ketoamides to afford 1,1-disubstituted tetrahydro-β-carbolines in excellent yields and enantiomeric excesses.
INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
申请人:Cottrell Kevin M.
公开号:US20090291902A1
公开(公告)日:2009-11-26
The present invention relates to compounds of formula I:
or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:
which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.